Cas:885523-89-7 Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate manufacturer & supplier

Chemical Name:Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate

CAS.NO:885523-89-7

Synonyms:6-Bromo-3-iodo-4-(1H)indazole methylncarboxylate;6-Bromo-3-iodo-4-(1H)indazole methyl carboxylate;Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate;1H-Indazole-4-carboxylic acid, 6-bromo-3-iodo-, methyl ester;methyl 6-Bromo-3-iodo-4-(1H)indazolecarboxylate

Molecular Formula:C₉H₆BrIN₂O₂

Molecular Weight:380.965

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:466.9±40.0 °C at 760 mmHg

Density:2.2±0.1 g/cm3

Index of Refraction:1.739

PSA:54.98000

Exact Mass:379.865723

LogP:3.81

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like 6-Bromo-3-iodo-4-(1H)indazole methylncarboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 6-Bromo-3-iodo-4-(1H)indazolecarboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo-3-iodo-4-(1H)indazole methylncarboxylate Use and application,methyl 6-Bromo-3-iodo-4-(1H)indazolecarboxylate technical grade,usp/ep/jp grade.

Related News: With the onset of the DMF system for APIs, the concentration of the API industry will further increase. Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate manufacturer INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate vendor According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017). Methyl 6-bromo-3-iodo-1H-indazole-4-carboxylate factory INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.